Latest News
- January 08, 2026Official press release: CBCC Global Research is now REV Clinical
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
May 09, 2024
Successful completion of 9 USFDA inspections
CBCC Global Research is proud to announce successful completion of 9 USFDA inspections since April 2022 for Oncology trials.
This is a result of commitment, hard work and dedication of our team towards our goal: CHANGING LIVES THROUGH HOPE AND INNOVATION